相关实验视频
Updated: Jul 20, 2025
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.8K
新彼得化物-B通过线粒体保护减轻了多克索鲁比诱导的心脏毒性
Chang Shin Yoon1, Nikolay E Nifantiev2, Dmitry V Yashunsky2
1Cardiovascular and Metabolic Disease Center, Smart Marine Therapeutics Center, Department of Physiology, College of Medicine, Inje University, Busan 47397, the Republic of Korea.
概括
新彼得化物-B (NPS-B) 通过改善线粒体功能来保护心脏细胞免受化疗药物多克索鲁比的毒性. 此外,NPS-B还通过降低癌细胞活力来表现出抗癌作用,这表明它具有作为双动疗法的潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- doxorubicin 是一种人环素化学疗法,可引起心脏毒性,原因是线粒体功能障碍.
- 在化疗期间保护心脏对于患者的治疗结果至关重要.
研究的目的:
- 调查Neopetroside-B (NPS-B) 对多克索鲁比引起的心脏毒性的保护作用.
- 评估NPS-B对心肌细胞和癌细胞的影响.
主要方法:
- 在暴露于多克索鲁比和NPS-B.的心肌细胞中评估线粒体功能 (ATP生产,氧消耗).
- 在用NPS-B治疗的癌细胞中分析了活性氧物种 (ROS) 和NAD+/NADH平衡.
- 利用代谢和蛋白质组分析来识别受影响的途径.
- 在 doxorubicin 治疗的异种移植小鼠模型中评估了 NPS-B 的疗效.
主要成果:
- NPS-B增强了心肌细胞中的线粒体功能,增加了ATP生产和氧气消耗.
- NPS-B在癌细胞中增加了ROS,降低了NAD+/NADH平衡,并降低了活力.
- 代谢物蛋白丰富揭示NPS-B影响心肌细胞中的 uracil 代谢和 NAD 结合蛋白.
- 在体内,NPS-B减少了心脏纤维化,并改善了与多克索鲁比治疗的小鼠的心脏功能.
结论:
- NPS-B证明了对多克索鲁比诱导毒性的心脏保护作用.
- 通过破坏癌细胞代谢,NPS-B表现出抗癌性质.
- NPS-B代表了一种有前途的治疗策略,可以缓解化疗引起的心脏毒性,同时保持抗癌疗效.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
625
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
625
01:46Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:29Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16